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repOrt
The alloimmunization potential of many RHD variants is 
unknown, and it can be explored by lookback and traceback 
studies. Héma-Québec (HQ) investigated the RHD status of 
3980 D– repeat blood donors. Thirteen were found to be RHD 
positive: 4 RHD*ψ, and 1 RHD*487delACAG, which show a D– 
phenotype; and 1 RHD*885T and 7 RHD*(93–94insT) causing 
a DEL phenotype when C antigen is present. Lookback studies 
were done to verify the alloimmunization potential of these eight 
DEL donors. Coincidentally, Canadian Blood Services (CBS) 
performed a traceback study by investigating the RHD status of 
donors after a D– recipient developed anti-D after transfusion of 
two D– red blood cell (RBC) units. Donor genotyping was done 
either manually (HQ) or using the Progenika Bloodchip platform 
(CBS). Donations were traced through computer records. Letters 
were sent to hospital blood bank physicians to verify the presence 
of anti-D in recipients and to donors to request repeat samples. 
A total of 118 RBC units were transfused, 82 to D– recipients. 
Anti-D was found in three patients transfused with RHD*(93–
94insT) DEL red blood cells. One donor presenting the same DEL 
variant was involved in the traceback study. Even without strong 
evidence clearly demonstrating the alloimmunization potential of 
DEL variants, whenever HQ or CBS identifies a donor harboring 
a DEL phenotype, his or her D status will be changed from D– 
to D+ to protect against the potential alloimmunization risk. 
Immunohematology 2013;29:136–140.
Key Words: DEL, RHD variant, alloimmunization, trans-
fusion reaction
RH blood group D antigen is the second most immuno-
genic, after ABO antigens. Antibodies to D are considered 
clinically significant because they have been associated with 
hemolytic transfusion reactions and hemolytic disease of the 
newborn.1–3 The D antigen expression is polymorphic and 
varies among populations. In whites, the D– phenotype is 
observed in 15 to 17 percent compared with 5 percent in black 
Africans and less than 3 percent in Asians. Many variants 
accounting for the D– phenotype have been observed and they 
vary among populations.1,4
The D antigen’s polymorphic nature is reflected by a wide 
range of partial or weak antigen expression, which led to the 
classification of variant D antigens: partial and weak. Partial 
D–expressing individuals could be alloimmunized when 
transfused with normal D+ red blood cells (RBCs), because 
some D epitopes are absent from their RBC membrane. On 
the other hand, weak D antigens are thought to cause less 
alloimmunization because the polymorphisms are located 
within transmembrane domains or intracellular regions, 
although these changes might alter the overall protein 
structure.3,5,6
A weak Ds subcategory consists of extremely weak RHD 
variants, termed DEL. A small amount of anti-D can be 
eluted from DEL RBCs after incubation with anti-D, although 
there is no agglutination by indirect antiglobulin test (IAT).7 
Normal D individuals might have as many as 20,000 sites per 
erythrocyte,6 whereas DEL individuals have between 20 and 
40.8 DEL individuals are mainly found in the Far East (10–
30% in China and Japan), although DEL phenotypes resulting 
from different RHD variants have been observed in whites. 
These variants are caused by RHD missense mutations, splice 
site mutations, or deletion of RHD exon(s).8–19
It is well established that some weak Ds and most DEL 
units are mistyped as D– by routine automated serologic 
methods used to type blood donors, posing a potential 
risk of anti-D immunization when transfused to D– 
recipients.4,7,14,17,20 To address this potential risk, blood centers 
may implement testing of every apparently D– donor. This 
can be accomplished by adapting the adsorption-elution 
technique used to detect the DEL phenotype to a higher 
throughput setting or by using molecular testing.14,20,21 
A Vox Sanguinis International Forum published in 2006 
summarized the practices of several blood centers regarding 
the use of molecular testing to detect RHD variants missed by 
IAT.22 The majority of centers did not routinely use molecular 
typing, but would consider it for C+ or E+ donors, implying 
that all D– donors would have to be typed for C and E before 
molecular analysis. Molecular typing was also considered 
when a discrepancy was observed between monoclonal 
reagents on serologic testing.
As for demonstrating the risk of alloimmunization, very 
few studies have been reported to date.4,7,9,15,22 Yasuda and 
collaborators published a clear case of secondary immunization 
after transfusion of DEL RBCs.7 Shao’s and Kim’s groups 
published alloimmunization cases involving East Asians.14,20 
In one of the cases, the recipient showed an anti-D after only 9 
IMMUNOHEMATOLOGY, Volume 29, Number 4, 2013 137
days. Other studies have focused on D immunization in weak 
D types.15
Alloimmunization potential can be identified by two 
different means: lookback and traceback studies. Lookbacks 
start by molecular typing of donors and subsequently 
investigate whether D– recipients are alloimmunized after a 
transfusion involving D variant donors. On the other hand, 
traceback studies are initiated when a D– recipient develops 
an anti-D after an apparent D– transfusion. Identification of 
the donors and molecular typing are performed.
In 2007, Héma-Québec (HQ) launched a large genotyping 
project for repeat whole blood donors.23–25 Four RHD variants 
were found among the D– donors: RHD*(93–94insT), RHD*ψ, 
RHD*(487delACAG), and RHD*885T.
RHD*ψ and RHD*(487delACAG) alleles have always 
been associated with a D– phenotype. The other two alleles, 
RHD*(93–94insT) and RHD*885T, are considered DEL in 
the presence of the C antigen. Nothing is known about their 
alloimmunogenicity.
Interestingly, the most frequent DEL phenotype found to 
date in Canadian blood donors is the result of variant allele 
RHD*(93–94insT) (7 of 3980 D– donors, 0.18%). All donors 
with this allele are likely of French Canadian ancestry. This 
allele was first reported in 2006 in one German donor,26 and 
examples reported since then include three in Spain,16 two 
in Germany,17 and one in Denmark.19 However, there is no 
information on the clinical importance of the allele in terms of 
alloimmunization potential.
The additional T in RHD*(93–94insT) causes a frameshift 
mutation that leads to a stop codon at amino acid position 
35. Such mutation early in a protein would be predicted 
to completely suppress antigen expression, but replication 
slippage may explain traces of functional protein.17
Preventing alloimmunization is a daily challenge for 
blood banks. However, little is known about the antigen 
density sufficient to cause an anti-D alloimmunization. Many 
D– recipients transfused with weak D type 1 and 2 were 
alloimmunized.27–29 The density of these weak Ds has been 
estimated to be between 400 and 1200.28,30 Gassner and 
colleagues published an alloimmunization case involving a 
weak D type 26 with an antigen density of 29 to 70.15
To evaluate the risk of alloimmunization from the eight 
DEL blood donors described earlier, HQ undertook a lookback 
study going back to 2000. Coincidentally, a traceback study 
was performed at Canadian Blood Services (CBS) to investigate 
anti-D alloimmunization in an elderly female recipient, 
reported by a hospital blood bank, involving two D– donors.
Materials and Methods
Donor Testing
Genotyping was originally done using the SNPstream 
Genotyping System (Beckman-Coulter, Fullerton, CA) and 
is described in detail elsewhere.23 Donor serologic typing was 
initially done using the Olympus PK7200 (Beckman-Coulter, 
anti-D P3X61+P3X21223B10+P3X290+P3X35 and PK2, 
Diagast, Loos, France). The D– status was confirmed using 
standard serologic methods (e.g., IAT). The DEL status of the 
eight HQ suspected DEL donors was confirmed by adsorption-
elution, following manufacturer’s instructions (Elukit Plus, 
Dominion Biologicals Limited, Dartmouth, Nova Scotia, 
Canada; anti-D D175–2+D415 1E4, Novaclone, Dominion 
Biologicals Limited).
Lookback Study
For D– recipients, hospital blood banks were asked to 
verify the presence of anti-D, and if it was identified before the 
transfusion of interest. Finally, they were asked whether any 
other blood products were transfused during the same period. 
Standard serology methods were used to identify anti-D.
Traceback Case
An 88-year-old woman with no previous transfusions 
and one pregnancy had a negative antibody screen on her 
admission at the hospital with an abdominal aortic aneurysm. 
Four weeks after she received two O, D– RBC units, her 
antibody screen tested positive and anti-D was identified. Both 
transfused units typed D– C+E-c+e+. An investigation was 
initiated including extended serologic D antigen testing by IAT 
using reagents from three different manufacturers (Novaclone; 
Gamma-clone, Immucor, Norcross, GA; and Bioclone, Ortho 
Diagnostic Systems, Markham, Ontario, Canada; using 
ALBAclone Advanced Partial RhD Typing kit, Penicuik, UK), 
and adsorption-elution (Elukit Plus, Dominion Biologicals 
Limited). RHD genotyping was performed by Progenika using 
the BLOODCHIP system (Novartis, Cambridge, MA).
Results
Lookback Study
Blood donations made by HQ’s eight DEL donors were 
traced through Progesa (Mak-System, Paris, France) as far 
as year 2000. Hospital blood banks that received the RBC 
units were notified in writing of the unusual D status of these 
donors. They were asked whether or not the RBC units had 
been transfused, and if so, to D+ or D– recipients.
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Letters were sent to 27 hospitals that received the 171 
traced RBC units. Information was available for 118 units that 
were transfused to 36 D+ recipients and 82 D– recipients. No 
further follow-up was pursued for the D+ recipients.
Antibody screening done several weeks after transfusion 
showed anti-D in three patients transfused with three units 
from different donors bearing the same RHD*(93–94insT) 
variant (Table 1). Recipients with anti-D also received other 
blood products during the same transfusion episode (Table 2). 
These patients were hospitalized for surgery (abdominal aortic 
aneurysm [n = 2] and cardiac surgery in a case of Marfan 
syndrome). Some of these products were platelets from D+ 
donors. None of the blood donors had anti-D, and we are not 
aware of their transfusion or pregnancy history.
Little information is available on the alloimmunization 
potential of RHD*11 RBC units in a CDe haplotype.31 This 
donor gave 11 units. We have information for seven of these 
units. Two were transfused to D– patients. The first patient 
had no anti-D, and the second was lost to follow-up.
Traceback Case
Of the two donors involved in this possible allo-
immunization event, one was confirmed D– by serologic 
methods and by genotyping. The other typed D– by IAT and 
the ALBA kit, but was determined serologically to be DEL by 
adsorption-elution. His genotype was found to be RHD*(93–
94insT). This donor lives in Nova Scotia (Canada) and is of 
Acadian descent, 17th-century French colonists in Canada. 
The lookback showed that three other RBC units from earlier 
donations were transfused. Two recipients remained antibody 
negative, and one was lost to follow-up.
Discussion
This study demonstrates the difficulties inherent in 
determining immunization potential in clinical settings. 
Investigators in the four cases reported could not 
completely determine the definitive cause of the observed 
alloimmunization because DEL RBCs were involved as well 
as apheresis platelets from D+ donors and a possible D+ 
pregnancy. At the very least, this DEL variant appears able 
to trigger a secondary immune response. Additionally, the 
frequency of alloimmunization appears higher in a traceback 
study, which starts with a potentially alloimmunized patient, 
compared with a lookback study, which starts with genotyped 
donors. As a precaution, HQ and CBS have adopted the policy 
that all known DEL donors will be considered as D+. They will 
be notified, and explanations will be provided.
From this study, we might speculate about the potential risk 
of DEL to immunize D– individuals. Even with a density of 20, 
a DEL RBC unit might contain on average 4 × 1013 D antigens, 
equivalent to 200 to 400 µL of normal D+ blood. Ogasawara et 
al. observed that anti-D–sensitized DEL erythrocytes were not 
phagocytosed in a monocyte phagocytosis assay, suggesting a 
low alloimmunization risk.32
Studies have shown that 200 mL of D+ blood could 
alloimmunize D– healthy individuals when booster doses 
were injected (500–1000 µL) after a 6-month rest period.33
The first three alloimmunization cases described in this 
work were also transfused with apheresis platelets. A study 
done at HQ showed an equivalent of 3 µL or 1.8 × 107 residual 
RBCs in apheresis platelets prepared on the Trima apparatus 
(Dr. Louis Thibault, personal communication). Recipient B 
received platelets before 2006; these platelets were prepared 
with the Spectra system. They might have contained more 
residual RBCs, but data are not available for our center.
Table 1. Red blood cell units from the three RHD*(93–94insT) donors possibly involved in antigen D alloimmunization
Donor
Total RBC units delivered  
to hospitals
Available information for 
transfused units
Units transfused to  
D– recipients
Number of recipients  
with anti-D
Number of recipients  
without anti-D Recipients lost to follow-up
1 34 23 19 1 12 6
2 33 21 14 1 9 4
3 28 21 14 1 7 6
Total 95 65 47 3 28 16
RBC = red blood cell.









A F/87 Yes 1 0 1 D+ (2006)
B F/88 Yes 1 0 1 D+ (2004)
C F/44 Unknown 1 6 1 D+ (2006)
CBS case F/88 Yes 1 0 0
*The apheresis process was modified at Héma-Québec in 2006. Before 
2006, the Spectra system was used. After 2006, the Trima Accel apparatus 
(Terumo BCT) was implemented.
RBCs = red blood cells, CBS = Canadian Blood Services.
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As for the CBS’ case, the antibody screen was positive 
4 weeks after transfusion. The earliest antibody response 
reported by Frohn and collaborators was 14 days33 and for 
Wagner et al., it might be as fast as 11 days.9 This patient gave 
birth to one child more than 40 years previously. The child’s D 
status is unknown to us; therefore, we are unsure whether this 
case represents primary alloimmunization or an anamnestic 
response.
Even without strong evidence clearly demonstrating 
the alloimmunization potential of DEL variants, whenever a 
donor harboring a DEL phenotype is identified, HQ and CBS 
practices will be to change the donor’s D status from D– to D+ 
to prevent the potential alloimmunization risk.
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